文献速递湿疹皮炎与荨麻疹

JAK抑制剂通过抑制T细胞糖酵解改善小鼠过敏性接触性皮炎

The Inhibition of Glycolysis in T Cells by a Jak Inhibitor Ameliorates the Pathogenesis of Allergic Contact Dermatitis in Mice.
PubMed 文献 · J Invest Dermatol · 2023-04-06

该研究在小鼠过敏性接触性皮炎(ACD)模型中评估JAK抑制剂鲁索替尼的作用,发现给药后炎症皮肤中CD4+ T细胞、CD8+ T细胞、中性粒细胞及可能的巨噬细胞数量减少,病理表现减轻;体外实验显示鲁索替尼下调分化T细胞中IL-2介导的糖酵解;T细胞特异性Pgam1缺陷小鼠不出现ACD症状。

要点

  • 鲁索替尼减少ACD小鼠炎症皮肤中CD4+ T细胞、CD8+ T细胞、中性粒细胞及可能的巨噬细胞数量。
  • 鲁索替尼在体外下调分化T细胞中IL-2介导的糖酵解水平。
  • T细胞特异性Pgam1缺陷小鼠不出现ACD症状,提示T细胞糖酵解对ACD发生重要。

核心结论

  • 鲁索替尼通过下调T细胞糖酵解抑制小鼠ACD发展,可能是重要因素。

研究设计与样本

  • 研究使用小鼠ACD模型评估鲁索替尼(JAK1和JAK2抑制剂)的效果。
  • 体外实验用鲁索替尼处理分化中的T细胞。
  • 使用T细胞特异性Pgam1缺陷小鼠验证T细胞糖酵解能力缺失的影响。

主要发现

  • 鲁索替尼给药后,ACD小鼠炎症皮肤中CD4+ T细胞、CD8+ T细胞、中性粒细胞及可能的巨噬细胞数量减少,病理生理表现减轻。
  • 体外鲁索替尼处理分化T细胞后,IL-2介导的糖酵解水平下调。
  • T细胞特异性Pgam1缺陷小鼠不出现ACD症状。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allergic contact dermatitis (ACD) and atopic dermatitis develop through delayed-type hypersensitivity reactions mediated by T cells. The development of immunomodulatory drugs, such as Jak inhibitors, would be useful for the long-term management of these diseases owing to their profile of favorable adverse effects. However, the efficacy of Jak inhibitors for ACD treatment has not been fully determined under a variety of settings. Therefore, we evaluated the effects of ruxolitinib, a Jak inhibitor for Jak1 and Jak2, using a mouse ACD model. As a result, the lower numbers of immune cells, including CD4+ T cells, CD8+ T cells, neutrophils, and possibly macrophages, as well as milder pathophysiological aspects have been observed in the inflamed skin of ACD with the administration of ruxolitinib. In addition, the treatment of differentiating T cells with ruxolitinib downregulated the level of IL-2-mediated glycolysis in vitro. Furthermore, symptoms of ACD did not develop in T-cell-specific Pgam1-deficient mice whose T cells had no glycolytic capacity. Taken together, our data suggest that the downregulation of glycolysis in T cells by ruxolitinib could be an important factor in the suppression of ACD development in mice.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Okamoto M, Omori-Miyake M, Kuwahara M, et al. The Inhibition of Glycolysis in T Cells by a Jak Inhibitor Ameliorates the Pathogenesis of Allergic Contact Dermatitis in Mice. J Invest Dermatol. 2023. PMID: 37028703. doi:10.1016/j.jid.2023.03.1667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。